Developer of Minimally Invasive Cardiovascular Treatment Devices

Click on the "blue words" above to follow more exciting content.

"The Art of Breaking Bamboo - Strategies and Practices for Reconstructing Branches Above the Aortic Arch"

Zhongshan Hospital Affiliated to Fudan UniversityProfessor Kang Xiao
First, Professor Tang Xiao analyzed the current status of endovascular treatment technology for aortic diseases. He pointed out that the current in-situ fenestration technology can fully match the patient's anatomical structure. The experience of Futhrough in-situ fenestration used by Fudan Zhongshan shows that the three-year patency rate is over 90%, but it requires the support of new instruments. The existing commercial main stent graft materials have irregular orifice shapes after being expanded during in-situ fenestration, or are not easy to puncture, or have strong rebound force, which can easily lead to occlusion and high risk of endoleaks.Percutek TherapeuticsWith meticulous dedication, clinical problems are effectively solved. Through innovative weaving technology, a main stent material that fits perfectly with in-situ fenestration has been developed. The material is divided into a conventional area and a new technology area. After expansion with a 9mm balloon at 7ATM, the fenestration diameter exceeds 5.5mm, with no fragmentation or detachment at the edges. Currently, it has shown excellent performance in over twenty real-world cases of in-situ fenestration for the left subclavian artery, and its safety and efficacy have been preliminarily verified. Professor Tang Xiao further shared his application experiences across multiple lesion cases, including aortic arch ulcers and aortic arch aneurysms.
"Breaking Bamboo Victory - Innovative Application of Domestically Produced Thoracic Devices"Main Stent TEVARSurgical Combined In-situ Reconstruction of LCCA+LSA

Beijing Anzhen Hospital, Capital Medical UniversityProfessor Yang Liao

Professor Liu Qiang mentioned that the future treatment of vascular diseases will surely be an individualized treatment pattern dominated by endovascular techniques, supplemented by hybrid surgery, and guaranteed by open surgery. In usePercutek TherapeuticsThe new process optimization of the covered stent allows for easy operation when performing in-situ reconstruction of the LSA through a guidewire, reducing the selection requirements for endovascular devices. Postoperative fenestrated stent morphology is regular with no leakage around, showing satisfactory results. Additionally, it demonstrates potential in the application of techniques such as the use of puncture kits or ex-vivo fenestration.Percutek TherapeuticsWhen using the Percutek Therapeutics® thoracic aortic stent graft for arch reconstruction, it is also appreciated for its precise positioning, secure anchoring, excellent sealing performance, appropriate radial support, superior flexibility and conformability, and ease of retrieval. For the treatment of arch-related dissections, intramural hematomas, penetrating ulcers, aneurysms, and other conditions, it can be selected.Percutek TherapeuticsThoracic aortic stent graft was used for treatment.
"Breakthrough Repair - Case Sharing of Residual End Management After Open Surgery for Thoracic Aortic Dissection"

"Rapid Thrombus Clearance - Strategies and Practices for Acute and Subacute Thrombus Management"

Professor Kang Haihan mentioned that for the treatment of deep vein thrombosis (DVT) in the lower limbs, percutaneous mechanical thrombectomy (PMT) or manual thrombectomy are currently the mainstream interventional surgical treatment methods, and contact catheter-directed thrombolysis (CDT) can be used when necessary. In addition, Professor Kang Haihan recommended addressing iliac vein stenosis in the first stage, which can reduce the risk of DVT recurrence caused by iliac vein stenosis and also lower the cost of secondary treatment for patients. Professor Kang Haihan specifically mentioned,Percutek TherapeuticsThrombolytic catheter, featuring an adjustable injection pump, 360° uniform and powerful spray, and a complete range of models. Its effective range covers the iliac vein and inferior vena cava, efficiently cooperating with mechanical or manual thrombus aspiration to treat DVT.
About Percutek Therapeutics
Beijing Percutek Therapeutics Medical Equipment Co., Ltd. is a high-tech enterprise focused on the research, development, and application of innovative products and therapies in the field of vascular disease treatment. Its main business includes the research, development, production, and sales of medical device products in the fields of aortic, peripheral and coronary, neuro-intervention, and access. The company adheres to self-research and development guided by addressing the clinical needs of patients with vascular diseases in China. Through the accumulation and application of innovative technologies, it continuously overcomes clinical challenges in the field of vascular disease treatment, providing doctors and patients with high-quality products and solutions for vascular disease treatment. The company is committed to becoming a platform-based medical device company rooted in China with world-class technology and competitiveness in the field of vascular disease treatment, benefiting patients with vascular diseases worldwide.
END

About Yuanbio Venture Capital

Yuansheng VenturesIt is an investment institution focused on the early and growth-stage healthcare sector, based in Suzhou BioBAY with a global reach. To date, it has completed investments in over 180 outstanding enterprises in the life sciences and healthcare field, covering four major areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as healthcare services, achieving substantial investment returns. Among these, 19 companies have gone public on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanSheng Venture Capital has been repeatedly ranked among the Top 10 venture capital funds in China's healthcare sector and recognized as one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, YuanSheng Venture Capital boasts extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging its expertise, focus, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.
